Myriad Genetics' growth potential lies in its innovative products, strong financials, and expanding market opportunities.

May is Mental Health Awareness Month and with 1 in 5 American adults (23.1% of the population) living with mental illness, ...

In the assessment of 12-month price targets, analysts unveil insights for Myriad Genetics, presenting an average target of ...

Fear of side effects prevents more than half of those diagnosed with treatable depression and anxiety from taking medications ...

Myriad Genetics had a negative return on equity of 4.51% and a negative net margin of 14.09%. The firm had revenue of $210.60 million for the quarter, compared to analyst estimates of $210.35 million.

Myriad Genetics will present new data on its Precise MRD test for renal cell carcinoma at the AACR Annual Meeting. Myriad Genetics, Inc. announced that it will present new clinical data on its ...

Podium presentation showcases the clinical application of Precise™ MRDSALT LAKE CITY, April 25, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic ...

Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth.

SALT LAKE CITY, April 29, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc (MYGN). (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its first quarter 2025 ...

Myriad Genetics (MYGN) announced that the Journal of Clinical Psychopharmacology has published a study showing those with major depressive ...

Myriad Genetics, Inc. announced that a study published in the Journal of Clinical Psychopharmacology found that the GeneSight® Psychotropic Test significantly reduced psychiatric hospitalizations ...

Summary: Myriad's Precise MRD test is an ultrasensitive second-generation hybrid-capture-based tumor-informed assay that ...